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Abstract: Background: Patients with chronic diseases frequently adapt their lifestyles to their func-
tional limitations. Functional capacity in Hypertrophic Cardiomyopathy (HCM) can be assessed
by stress testing. We aim to review and analyze the available data from the literature on the value
of Cardiopulmonary Exercise Test (CPET) in HCM. Objective measurements from CPET are used
for evaluation of patient response to traditional and new developing therapeutic measurements.
Methods: A systematic review of the literature was conducted in PubMed, Web of Science and
Cochrane in Mar-20. The original search yielded 2628 results. One hundred and two full texts were
read after the first screening, of which, 69 were included for qualitative synthesis. Relevant variables
to be included in the review were set and 17 were selected, including comorbidities, body mass
index (BMI), cardiac-related symptoms, echocardiographic variables, medications and outcomes.
Results: Study sample consisted of 69 research articles, including 11,672 patients (48 ± 14 years old,
65.9%/34.1% men/women). Treadmill was the most common instrument employed (n = 37 studies),
followed by upright cycle-ergometer (n = 16 studies). Mean maximal oxygen consumption (VO2max)
was 22.3 ± 3.8 mL·kg−1·min−1. The highest average values were observed in supine and upright
cycle-ergometer (25.3± 6.5 and 24.8± 9.1 mL·kg−1·min−1; respectively). Oxygen consumption in the
anaerobic threshold (ATVO2) was reported in 18 publications. Left ventricular outflow tract gradient
(LVOT) > 30 mmHg was present at baseline in 31.4% of cases. It increased to 49% during exercise.
Proportion of abnormal blood pressure response (ABPRE) was higher in severe (>20 mm) vs. mild hy-
pertrophy groups (17.9% vs. 13.6%, p < 0.001). Mean VO2max was not significantly different between
severe vs. milder hypertrophy, or for obstructive vs. non-obstructive groups. Occurrence of arrhyth-
mias during functional assessment was higher among younger adults (5.42% vs. 1.69% in older adults,
p < 0.001). Twenty-three publications (9145 patients) evaluated the prognostic value of exercise capac-
ity. There were 8.5% total deaths, 6.7% cardiovascular deaths, 3.0% sudden cardiac deaths (SCD), 1.2%
heart failure death, 0.6% resuscitated cardiac arrests, 1.1% transplants, 2.6% implantable cardioverter
defibrillator (ICD) therapies and 1.2 strokes (mean follow-up: 3.81 ± 2.77 years). VO2max, ATVO2,
METs, % of age-gender predicted VO2max, % of age-gender predicted METs, ABPRE and ventricular
arrhythmias were significantly associated with major outcomes individually. Mean VO2max was
reduced in patients who reached the combined cardiovascular death outcome compared to those who
survived (−6.20 mL·kg−1·min−1; CI 95%: −7.95, −4.46; p < 0.01). Conclusions: CPET is a valuable
tool and can safely perform for assessment of physical functional capacity in patients with HCM.
VO2max is the most common performance measurement evaluated in functional studies, showing
higher values in those based on cycle-ergometer compared to treadmill. Subgroup analysis shows
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that exercise intolerance seems to be more related to age, medication and comorbidities than HCM
phenotype itself. Lower VO2max is consistently seen in HCM patients at major cardiovascular risk.
Keywords: hypertrophic cardiomyopathy; physical activity; exercise test; pathophysiology; prognosis
1. Introduction
Hypertrophic cardiomyopathy is the most frequent and best characterized inheritable
cardiac disease (1:500 general population). It is defined by the presence of left ventricular
hypertrophy (LVH), measured as thickness of ≥15 mm in adults, in the absence of other
loading conditions [1,2]. HCM causes significant morbidity and mortality, and its natural
history includes the development of atrial and ventricular arrhythmias such as atrial
fibrillation or flutter, and heart failure, stroke, and sudden cardiac death. SCD is the most
frequent severe event with a 1% annual incidence [2,3]. In some developed countries, HCM
is the most important cause of SCD among young people and athletes [3].
A series of clinical parameters associated with an increased risk of SCD during the
follow-up of these patients have been identified. These include the magnitude of the LVH,
severity of the left ventricular outflow tract gradient, left atrial diameter, familiar history of
syncope or SCD, and the non-sustained ventricular tachycardia (NSVT) in the ambulatory
ECG monitoring [4–7] but also ABPRE and the presence of ventricular arrhythmias. While
every parameter has low predictive value when considered alone, risk scores derived from
population size sample of patients have been developed [4,5]. HCM patients’ response
to exercise has been largely studied. Values of VO2max and ATVO2 have been found
reduced in some series. When functional limitation is present, this can be explained related
to a reduction in the stroke volume, the chronotropic reserve, an imbalanced ventilation
perfusion, and an inadequate peripheral oxygen utilization.
Patients with chronic diseases frequently adapt their lifestyles to the functional limita-
tions associated with their pathology. Exercise testing in HCM patients is a useful tool to
reveal subclinical symptoms and provides valuable information for exercise prescription [8].
HCM patients’ response to exercise has been widely investigated and even proposed as
one of the differential diagnostic variables between cases of physiological hypertrophy in
athletes and HCM [9,10].
While a comprehensive assessment of functional capacity with ergometry, VO2max
analysis with echocardiography allows a better understanding of the pathophysiology in
HCM, the diversity of protocols prevents from comparisons between studies. Dyspnea,
chest pain, and syncope on exertion are a consequence of the complex involvement of
cardiac and extracardiac factors. LVOT together or not with mitral regurgitation, diastolic
dysfunction, myocardial ischemia, rhythm disorders, or autonomic imbalance, are the main
cardiac factors involved in symptoms development.
The main aim of the study was to present a systematic review and a meta-analysis
of the of available data on cardiopulmonary exercise functional assessment of patients
with HCM. The analysis included the evaluation of methodological protocols and the
impact of relevant clinical characteristics such as age group, obstruction severity, degree of
hyper-trophy and the prognostic implications of the results of the functional tests.
2. Experimental Section
2.1. Eligibility Criteria
Publications indexed in the Journal Citation Report (JCR) with cross-sectional, case–
control, cohorts, randomized controlled trial, clinical trial or case study designs were
included. Manuscripts had to be written in English, without restrictions regarding publi-
cation date. Systematic reviews, meta-analysis and narrative reviews were not included.
According to PICOS strategy, investigations had to assess maximal functional capacity
in hypertrophic cardiomyopathy patients in absence of other cardiac diseases. Exercise
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cessation criteria had to be at least one among event development, limiting symptoms or
fatigue impeding continuation. Interventions based on pharmacological treatment, exercise
training, surgery, alcohol septal ablation, lifestyle modifications or the combination of
them were included. Comparation groups considered for inclusion were healthy controls,
athletes, or patients with or without LVOT. Finally, studies without comparation group
describing some aspect related to the pathology and accomplishing the aforementioned
criteria were considered as well.
2.2. Search Strategy
A systematic review of the literature was conducted on PubMed, Web of Science
and Cochrane in March 2020. Topics for the search were set throughout a brainstorming
session, including keywords according three main areas: HCM, physical exercise and
functional capacity: hypertrophic cardiomyopathy, cardiac rehabilitation, physical exercise,
exercise tolerance, exercise capacity, anaerobic threshold, maximal oxygen consumption,
athlete, assessment, evaluation e intervention. Final search was (((((physical activity[Title])
OR physical exercise[Title]) AND intervention[Title]) OR trial[Title]) OR random*[Title])
AND hypertrophic cardiomyopathy[Title]; and (hypertrophic cardiomyopathy[Title]) AND
(physical activity OR physical exercise OR aerobic capacity OR athlete OR anaerobic
threshold OR maximal oxygen consumption) AND (assessment OR evaluation OR test *).
2.3. Data Extraction and Synthesis
Relevant variables to be included in the review were set and 17 were selected: sample
size, age, gender, inclusion of control group, assessment of extracardiac variables, man-
agement of pharmacological therapy, material used for the functional assessment, initial
intensity and its augments, time lapse for each intensity stage, VO2max, ATVO2, presence
of LVOT > 30 mmHg, mitral regurgitation, pulmonary capillary wedge pressure (PCWP),
ABPRE and occurrence of cardiac events.
When data were reported in different units, they were synthesized into equal magni-
tudes according to formulas mentioned for each case. When values were not explic-
itly indicated, they were calculated from other available data when possible. When
BMI was not reported but so were height and weight, it was determined as follows:
BMI = weight/height2 [11]. When previous fasting was ≥12 h it was considered together
with those reported as ‘overnight’. When speed (V) was reported in miles per hour (mph)
it was transformed into kilometers per hour (km·h−1) as follows: Vkm·h−1 × 1.609. When
maximal aerobic capacity was expressed in metabolic equivalents (METs), it was recalcu-
lated to ml·kg−1·min−1 of oxygen consumption as previously indicated [12], i.e., a maximal
work rate reached at 7 METs on a cycle-ergometer multiplied by 3.5 to be recalculated into
24.5 mL·kg−1·min−1.
2.4. Statistical Analyses
Global mean values and standard errors were calculated as the summatory of the
product of each class mark multiplied by its frequency and divided by the sample size. The
prevalence of extracardiac variables and inclusion of the assessment of cardiac variables in
the studies was evaluated as the summatory of cases divided by the sample size. Random
effects meta-analyses and subgroup analyses were performed using Review Manager
(RevMan), V.5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration,
2014). Differences in the prevalence of ABPRE and arrhythmia before and during exercise
were analyzed using a Chi-Square test on SPSS v.23. Alpha was set on 0.05.
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3. Results
3.1. Study Sample
Original search yielded 2616 results and 12 more were added based on the explo-
ration of the references of systematic reviews and meta-analyses related to hypertrophic
cardiomyopathy. When full texts were not available online, authors were contacted after
an initial screening for title and abstract. A flow diagram of the search process is avail-
able in Figure 1. One hundred and two full texts were read after the first screening, of
which, 69 were included for qualitative synthesis. The protocol was designed ad hoc and
not published. All data concerning methodological designs are showed in Table 1. They
included 11,672 patients which were 48 ± 14 years old and had an average body mass
index of 26.9 ± 6.5 kg/m2 as evaluated with data from 21 studies and 6558 patients. In
total, 65.9% of them were men and 34.1% women. In 18 of the 69 articles, at least one
extracardiac variable was included, among which the presence of diabetes and pathologies
involving the lipidic metabolism were the most common with 14 and 7 times reported,
respectively. The presence of diabetes was calculated with data from 3665 patients with a
prevalence of 7.6%; and from 1927 patients for dyslipidemias with a prevalence of 45.1%.
Other comorbidities such as hypertension and smoking habit were present in 32.8% and
30.6% of patients, respectively.
Figure 1. Flow diagram of the search process. Adapted from Moher and collaborators [13].
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Table 1. Methodological characteristics of publications.






Initial Added Lapse LVOT MR PCWP ABPRE Events
Abozguia, 2010 [14] 56 52 ± 11 29 Treadmill 4.7 M 2–3 M 3′ Not controlled - Out - - - -
Aljaroudi, 2012 [15] 495 50 ± 15 32 Treadmill 4.7 M 2–3 M 3′ Disc. (12 h) DM, HL BL BL - - Out
Arena, 2008 [16] 83 38 ± 10 39 Upright CE 15 W 15 W 1′ Continued - Out Out BL, Ex - -
Austin, 2010 [17] 50 44 ± 13 38 Treadmill - - - Continued - BL, Ex BL - Ex -
Axelsson, 2016 [18] 130 52 ± 13 35 Upright CE 25 W 25 W 2′ Continued - BL - - - BL
Azarbal, 2014 [19] 265 52 ± 15 39 Treadmill 2 mph - - Continued DM, HL BL BL - Ex -
Binder, 2007 [20] 217 56 ± 16 41 - - - - Not registered Creatinine BL BL - - -
Bonow, 1985 [21] 70 47 47 Treadmill 2 mph 2.5% 2′ Administered - BL - - - Ex
Briguori, 1999 [22] 52 41 29 Upright CE 60 rpm 1 W 3” Disc. (5H-L) - BL BL - Ex Ex
Briguori, 2001 [23] 44 40 ± 15 27 (?) CE 60 rpm 1 W 3” Disc. (5H-L) Blood analysis BL BL - - Ex
Chan, 1990 [24] 13 42 ± 14 38 Upright CE 28 W 22 W 3′ Administered - BL - BL - Out
Chikamori, 1992 [25] 81 41 46 Treadmill 4.7 M 2–3 M 3′ Disc. (?) - BL Out - Out Out
Choi, 2008 [26] 32 55 ± 11 19 Supine CE 25 W 25 W 3′ Disc. (?) Creatinine, HL BL Out - - -
Ciampi, 2007 [27] 22 36 ± 13 23 Treadmill 2.7 M 2–3 M 3′ Disc. (5H-L) - BL - - Ex Ex
Coats, 2014 [28] 1898 47 ± 15 33 Upright CE 0 W 10–30W 1′ Continued - BL BL - Ex Ex
D’Andrea, 2017 [29] 45 38 ± 15 22 Supine CE - 25 W 2′ No drugs used - BL - BL, Ex - -
de la Morena, 2003 [30] 98 44 ± 15 28 Treadmill 4.7 M 2–3 M 3′ Disc. (48 h) - BL BL - Ex Ex
de la Morena, 2013 [31] 87 54 ± 13 33 Treadmill 4.7 M 2–3 M 3′ Not controlled - BL, Ex BL, Ex - Ex Ex
Desai, 2014 [32] 426 44 ± 14 22 Treadmill 4.7 M 2–3 M 3′ Continued DM BL, Ex BL, Ex - Ex Ex
Dimitrow, 1996 [33] 10 37 ± 7 - Treadmill 2.7 M 2–3 M 3′ Administered DM, HL BL - - - -
Dumont, 2007 [34] 64 51 ± 14 33 Treadmill 4.7 M 2–3 M 3′ Disc. (72 h) - BL - - Ex BL
Efthimiadis, 2011 [35] 68 45 ± 15 34 Treadmill 4.7 M 2–3 M 3′ Not controlled - BL - - Ex BL
Ferguson, 2016 [36] 22 14 ± 3 44 Upright CE 25 W 25 W 3′ Continued - BL, Ex - - - -
Finocchiaro, 2015 [37] 156 51 ± 14 38 Treadmill - - - Continued - BL BL - - -
Frenneaux, 1989 [38] 23 30 39 Treadmill 2.7 M 2–3 M 3′ Continued - BL Out BL, Ex - BL
Ghiselli, 2019 [39] 292 46 ± 16 28 Semisup CE - 25 W 2′ Continued DM BL, Ex BL, Ex - Ex BL, Ex
Ha, 2005 [40] 29 57 ± 10 16 Supine CE 25 W 25 W 3′ Disc. (?) DM - - - - -
Hernández, 2015 [41] 40 55 ± 12 36 Treadmill 2.7 M 2–3 M 3′ Not registered DM BL - - - -
Jones, 1998 [42] 50 35 ± 14 30 Upright CE 0 W 5–15 W 1′ Disc. (48 h) - BL - - Out Ex
Kim, 2004 [43] 21 49 ± 15 43 Treadmill 4.7 M 2–3 M 3′ Administered - BL - - - -
Kitaoka, 2009 [44] 31 52 ± 17 35 Upright CE 0 W 15 W 1′ Continued - BL - - Ex -
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Table 1. Cont.






Initial Added Lapse LVOT MR PCWP ABPRE Events
Kjaergaard, 2005 [45] 99 49 ± 15 34 Treadmill 2 mph 2 M 2′ Continued - BL BL Out - -
Konecny, 2015 [46] 198 53 ± 16 38 Treadmill 2.5 M 2,5 M 2′ Continued DM, ∑skinfold BL BL - - -
Lafitte, 2013 [47] 107 52 ± 15 33 Semisup CE - - - Continued - BL, Ex BL - - Ex
Larsen, 2018 [48] 510 51 ± 15 36 Treadmill - 2 M 2′ Disc. (?) - BL BL - - BL
Le, 2009 [49] 63 48 ± 15 28 Treadmill - - - Continued DM, HL BL, Ex BL, Ex - Ex Ex
Lele, 1995 [50] 23 30 39 SupC + Tread 25 W 12.5 W 3′ Discont. (120 h) - BL BL BL, Ex Ex BL, Ex
Lösse, 1983 [51] 122 42 ± 3 - Supine CE - - - Administered - BL, Ex - BL, Ex Ex -
Luo, 2015 [52] 273 50 ± 15 30 Treadmill 2.7 M 2–3 M 3′ Not registered - BL, Ex - - Ex Ex
Ma, 2014 [53] 27 54 ± 12 42 Treadmill 2.7 M 2–3 M 3′ Not registered DM BL, Out BL, Out - - -
Magri, 2014 [54] 180 47 ± 16 25 Upright CE 0 W - - Continued - BL - - - -
Magri, 2016 [55] 683 49 ± 16 31 Supine CE - - - Continued DM BL - - Ex Ex
Magri, 2018 [56] 767 48 ± 16 32 (?) CE 0 W 5–15 W - Not controlled - BL - - Ex BL, Ex
Malek, 2009 [57] 13 - - Treadmill - - - Not registered - - - - - -
Matsumoto, 2005 [58] 27 35 33 Treadmill - 0.5% 1′ Continued - BL, Out BL - - -
Matsumura, 2002 [59] 85 38 ± 14 34 Upright CE 0 W 5–15 W 1′ Disc. (5H-L) - BL Out - - -
Menon, 2008 [60] 88 14 25 Treadmill 2.7 M 2–3 M 3′ Not registered - BL BL - - -
Miki, 1990 [61] 22 47 ± 15 18 Treadmill 2.7 M 2–3 M 3′ Disc. (120 h) - - - BL, Ex - -
Mizukoshi, 2013 [62] 33 59 ± 16 27 Semisup CE 20 W 1–2 W 6” Continued - Out - - - Ex
Moneghetti, 2017 [63] 131 52 ± 13 37 Treadmill - - - Not controlled - BL BL - Ex BL
Nihoyannopoulos,
1992 [64] 40 41 45 Treadmill 2.7 M 2–3 M 3
′ Continued - BL BL - - -
Nistri, 2010 [65] 74 45 ± 16 28 Upright CE - 25 W 2′ Disc. (5H-L) - BL, Ex BL - - Ex
Payá, 2008 [66] 120 47 ± 16 30 Treadmill 4.7 M 2–3 M 3′ Not registered - BL - - Ex BL
Peteiro, 2012 [67] 239 52 ± 15 39 Treadmill 2.7 M 2–3 M 3′ Continued DM, HL BL, Ex BL, Ex - Ex BL, Ex
Pozios, 2018 [68] 95 49 ± 16 31 Treadmill 2.7 M 2–3 M 3′ Continued DM, HL BL, Ex - - - Ex
Re, 2017 [69] 197 45 ± 15 35 Upright CE - 10W 1′ Disc. (72 h) - BL, Ex BL - Ex Out
Romero, 2008 [70] 98 46 ± 15 29 Treadmill 2.7 M 2–3 M 3′ Not registered - BL - - Ex BL
Rosing, 1979 [71] 27 44 ± 3 41 Treadmill 2 mph 2.5% 2′ Administered - BL - BL - -
Sachdev, 2005 [72] 43 36 ± 10 40 Upright CE - 15 W - Not registered - Out BL BL, Ex - -
Saura, 2009 [73] 75 46 ± 14 25 Treadmill 4.7 M 2–3 M 3′ Disc. (48 h) DM BL - - Ex BL
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Initial Added Lapse LVOT MR PCWP ABPRE Events
Shah, 2019 [74] 9 29 ± 8 0 Upright CE 0 W 20 W 1′ Continued Blood analysis Out - - - Ex
Shizukuda, 2005 [75] 49 36 ± 10 41 Upright CE - 5 W - Not registered - Out - BL, Ex - -
Smith, 2018 [76] 589 51 ± 14 39 Treadmill - - - Continued - BL - - - -
Smith, 2018 [77] 1177 53 ± 14 43 Treadmill - 2 M 2′ Continued DM, HL, Hb BL - - Ex -
Thaman, 2006 [78] 171 46 ± 18 63 Upright CE - 10–25W 1′ Continued - BL - - - BL
Wu, 2019 [79] 67 53 ± 11 12 Semisup CE 25 W 25 W 2′ Disc. (24 h) - Out - - - -
Wu, 2019 [80] 88 52 ± 12 14 Semisup CE 25 W 25 W 2′ Disc. (24 h) - BL - - - -
Wu, 2019 [81] 76 48 ± 12 20 Semisup CE 25 W 25 W 2′ Disc. (24 h) - BL, Ex - Ex Ex -
Yetman, 2001 [82] 17 12 ± 3 30 Treadmill 4.7 M 2–3 M 3′ Not controlled - BL, Ex BL - - -
%W: percentage of women in the sample; CPET: cardiopulmonary exercise test; BL: baseline measure; EX: exercise measure; Out: exclusion criteria; CE: cycle-ergometer; Sup CE: supine cycle-ergometer; Semisup CE:
semi-supine CE; Tread: treadmill; (?) CE: cycle-ergometer with unknown position of the patient; 5H-L: 5 half-lives; Disc.: drug therapy withdrawn a certain time before the test; Discont. (?): drug therapy withdrawn before
the test but no further information about time available; ‘M’: METs; DM: diabetes mellitus; HL: hyperlipidemia; ∑skinfolds: summatory of three skinfolds; Hb: hemoglobin content. ‘Not controlled’: drug use reported
without information about its management. When added intensity is reported with ‘%’, it means that slope of the treadmill was augmented in that certain percentage.
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Management of the pharmacological therapy showed 12 different options and was
evaluated in 60 of the 69 studies. In seven of them, the use of drugs was recorded but
no further information about its management was provided. In 26 of the 53 remaining,
drugs were not discontinued before the study; in 6, the researchers provided it; and in 1,
none of the subjects were on medication. Finally, in the 20 remaining studies, drugs were
discontinued with variable time from 5 days to 12 h prior to the exercise test.
Treadmill was the most common ergometer employed (n = 37 studies), followed
by upright cycle-ergometer (n = 16 studies), supine and semi-supine cycle-ergometers
(n = 6 studies each). Bruce’s protocol [83] and its modified version [84] were the most
frequently used, while there was a marked heterogeneity in the protocols employed in the
cycle-ergometers. The initial intensity was set between 0 W and 28 W with increments
ranging from 5 W to 30 W and lapses lasting 1 to 3 min. There were 2 publications where
the intensity was increased in a ramp-like fashion adding 1–2 W each 1–6 s.
3.2. Maximal Oxygen Consumption
Maximal oxygen consumption was reported in 54 of the 69 texts and 51 of them were
included in a semi-meta-analysis to calculate the average values achieved in the literature
and to elucidate on which ergometer showed higher values. Data from 2 studies were not
included because of lack of information about patients’ position on the cycle-ergometer
and from 1 study because of lack in standard deviation information. Moreover, ATVO2
was indicated in 18 publications and 15 of them were included in semi-meta-analysis. Data
from 3 studies were not included as values of standard deviation were unavailable. Data of
each individual study are shown together with the mean values recorded in each ergometer
and the average VO2max in Figure 2. Mean VO2max was 22.3 ± 3.8 mL·kg−1·min−1,
while the highest average values were observed in supine and upright cycle-ergometer:
(25.3 ± 6.5 and 24.8 ± 9.1 mL·kg−1·min−1; respectively). Semi-supine cycle-ergometer
and treadmill showed lower mean VO2max (22.0 ± 5.3 and 21.9 ± 3.1 mL·kg−1·min−1;
respectively; although differences did not reach significance: p = 0.87 for all groups;
p = 0.57 for comparison between upright cycle-ergometer vs. treadmill). Mean ATVO2 was
14.6 ± 4.5 mL·kg−1·min−1 and data of each study are shown in Figure 3. According to this,
ATVO2 represented a 65.5% of VO2max.
3.3. Cardiac Variables
Data regarding cardiac variables were registered as included or non-included together
with the moment when measuring was done. Numerical data (not shown) were analyzed
separately and will be mentioned hereafter. Average prevalence of resting LVOT > 30
mmHg was 31.4% in 7933 patients and increased to 49% in exercise conditions (data from
1095 patients), meaning 1 out of 3 patients without resting LVOT > 30 mmHg developed
obstruction with exercise (287 out of 847).
Mitral regurgitation (MR) was evaluated in 27 publications: 22 at rest and 5 at rest and
during exercise. Prevalence of resting MR data was 33.9% (n = 5587) with no distinction of
the MR grade and augmented up to 62.0% during exercise.
Mean PCWP and pulmonary artery diastolic pressure during exercise was obtained
with data from 175 patients (11.9 ± 5.6 and 12.0 ± 5.8 mmHg, respectively), while average
values for pulmonary artery systolic pressure and mean pulmonary artery pressure were
28.5 ± 7.7 and 15.8 ± 5.0 mmHg, respectively.
Mean prevalence of ABPRE was 20.3%, but the available data prevented distinctions
between ABPRE type (e.g., blood pressure drop, failure in increasing blood pressure).
Regarding arrhythmias, 1496 (32.7%) patients experienced this event during 24 h
Holter monitoring prior to the CPET and 2.67% of them developed it during the test.
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Figure 2. Meta-analysis of the VO2max reported on each study and average values for each ergometer used on the
assessment of functional capacity. Grey points represent the average value of each individual study. Darker horizontal
lines intersecting them represent the upper and lower value of the mean ± SD, and lighter horizontal lines show 95% CI.
White rhombi intersected by a black line represent the mean VO2max and 95% CI of each ergometer as extracted from the
meta-analysis. The black rhombus represents the mean value and 95% CI of all studies as extracted from the meta-analysis.
Numerical values of each subgroup and the whole group are presented.
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Figure 3. Meta-analysis of the ATVO2 reported on each study. Grey points represent Table 2 of each individual study.
Darker horizontal lines intersecting them represent the upper and lower value of the mean± SD, and lighter horizontal lines
show 95% CI. The black rhombus represents the mean value and 95% CI of all studies as extracted from the meta-analysis.
Numerical values for the whole group are presented.
3.4. Analysis of Subgroups
Information from publications was extracted and sorted regarding age, presence of
baseline LVOT, and severity of hypertrophy.
Age cut-offs were arbitrarily set. Figure 4 represents VO2max for three pediatric
(n = 127), 19≤ 45 years old (n = 1496) and 30 > 45 years old (n = 5088) cohorts extracted infor-
mation from related publications. Mean VO2max was higher for adults≤ 45 years old, then
pediatric HCM patients and older adults, although differences did not reach significance
(25.6 ± 3.6 mL·kg−1·min−1 vs. 23.7 ± 6.6 mL·kg−1·min−1 and 22.5 ± 2.5 mL·kg−1·min−1,
respectively, p = 0.61 for young adults vs. pediatric, p = 0.15 for young vs. older adults).
Proportion of ABPRE was higher in young adult and older adult groups compared to
pediatric (20.4% vs. 14.2% and 2.75%, respectively, p < 0.001 for all groups and for paired
comparisons). Prevalence of previous arrhythmias was higher for older adults than for
younger adults (26.4% vs. 21.5%, p < 0.01), while the occurrence during functional assess-
ment was higher among younger adults (5.42% vs. 1.69% in older adults, p < 0.001). There
were no data regarding the presence or occurrence of arrhythmias in pediatric patients.
A 20 mm cut-off, which is close to the mean maximal left ventricular wall thickness
for most publications, was arbitrarily set for mean VO2max comparison. Figure 5 rep-
resents VO2max results of 22 and 26 publications with available information for under
and above 20 mm analysis. A total of 2600 patients were included in the milder and
3798 patients in the group with more severe hypertrophy. The group with more severe
hypertrophy had a higher mean VO2max, although differences did not reach significance
(24.4 ± 2.9 mL·kg−1·min−1 vs. 22.4 ± 2.6 mL·kg−1·min−1, p = 0.34). Proportion of ABPRE
was higher in severe vs. mild hypertrophy groups (17.9% vs. 13.6%, p < 0.001). The
prevalence of previous arrhythmias and occurrence during functional assessment was
similar in mild versus severe hypertrophy groups (26.5% vs. 24.5%, p = 0.44 and 2.79% vs.
2.11%, p = 0.26, respectively).
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Figure 4. Meta-analysis of the VO2max reported on each study and average values for each age group. Grey points
represent the average value of each individual study. Darker horizontal lines intersecting them represent the upper and
lower value of the mean ± SD, and lighter horizontal lines show 95% CI. White rhombi intersected by a black line represent
the mean VO2max and 95% CI of each age group as extracted from the meta-analysis. Numerical values of each subgroup
are presented.
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Figure 5. Meta-analysis of the VO2max reported on each study and average values for MWT groups. Grey points represent
the average value of each individual study. Darker horizontal lines intersecting them represent the upper and lower value
of the mean ± SD, and lighter horizontal lines show 95% CI. White rhombi intersected by a black line represent the mean
VO2max and 95% CI of each MWT group as extracted from the meta-analysis. The numerical values of each subgroup
are presented.
Information on exercise mean VO2max was available for comparison between baseline
LVOT ≥ 30 mmHg (n = 1529) and LVOT < 30 mmHg (n = 3346) and is shown in Figure 6.
Mean VO2max was slightly higher for obstructive vs. non-obstructive series, although
differences did not reach significance (25.2 ± 4.9 vs. 22.8 ± 3.1 mL·kg−1·min−1, p = 0.41).
Proportion of ABPRE was higher in non-obstructive versus obstructive groups (12.8% vs.
7.1%, p < 0.001). Prevalence of previous arrhythmias was 30.7% in non-obstructive patients,
while no data was available for obstructive groups. Occurrence of arrhythmia during
functional assessment was similar in obstructive and non-obstructive groups (5.55% vs.
4.08%, p = 0.29).
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Figure 6. Meta-analysis of the VO2max reported on each study and average values for each LVOT group. Grey points
represent the average value of each individual study. Darker horizontal lines intersecting them represent the upper and
lower value of the mean ± SD, and lighter horizontal lines show 95% CI. White rhombi intersected by a black line represent
the mean VO2max and 95% CI of each LVOT group as extracted from the meta-analysis. The numerical values of each
subgroup are presented.
3.5. Prognostic Studies
23 publications evaluating the prognostic value of exercise capacity for prediction
of major cardiac complications were identified. A total of 9145 patients were included in
this analysis. Table 2 summarizes main characteristics and results of the selected stud-
ies. Sixteen studies reported on SCD or equivalent (resuscitated cardiac arrest and ICD
therapies), 13 on heart failure death, 7 on stroke-related death, 8 on heart transplantation,
19 on global cardiovascular mortality and 14 on all-cause mortality. There were 8.47%
total deaths, 6.72% cardiovascular deaths, 3.06% SCD cases, 1.20% heart failure death,
0.65% resuscitated cardiac arrests, 1.01% transplants, 2.58% ICD therapies and 1.22 strokes.
Mean follow-up of the cohorts was 3.81 ± 2.77 years for a total of 43,794 patient years
followed. SCD was assessed in 5519 patients and occurred in 232 of them with an incidence
of 7.1 cases per 1000 patient−1 years−1. Appropriate implantable cardioverter defibrilla-
tor discharge was present in 110 cases among 4258 patients, with an incidence rate (IR)
of 5.4 cases per 1000 patient−1 years−1. Heart failure-related death was considered in
4594 patients and occurred in 55 of them with an (IR) of 2.4 per 1000 patient−1 years−1.
Resuscitation from sudden death was successfully achieved in 27 out of 4173 patients
(IR: 1.3 per 1000 patient−1 years−1). Stroke occurred in 41 cases among 3361 patients
(IR: 2.4 per 1000 patient−1 years−1). Forty patients had heart transplantation (IR: 2.1 per
1000 patient−1 years−1). Finally, cardiovascular and all-cause mortality were assessed in
6797 and 5594 patients, with an IR of 13.9 and 16.3 per 1000 patient−1 years−1, respectively.
J. Clin. Med. 2021, 10, 2312 14 of 24
Table 2. Characteristics of prospective studies.
Author, Year n Age %W F-up Drug Therapy
Prospective Outcomes (Cases)
SCD ICD HFm Res Str HT CVm All
Caselli, 2014 [85] 25 26 0 4.0 Not controlled 0 - 0 - - - 0 0
Coats, 2014 [28] 1898 47 33 5.6 Continued 40 - 31 - - 22 117 178
Desai, 2014 [32] 426 44 22 8.7 Continued 30 13 7 0 8 - 37 40
Feneon, 2016 [86] 126 47 22 2.4 Continued - 1 - 3 - - 7 -
Finocchiaro, 2015 [37] 156 51 38 2.3 Continued - - - - - 5 4 -
Ghiselli, 2019 [39] 292 46 28 5.9 Continued 1 - - 1 13 - 6 -
Gimeno, 2009 [87] 1380 42 38 4.5 Not controlled - - - - - - 158 -
Limongelli, 2019 [88] 51 39 24 1.8 Not controlled 0 - 0 - - - 0 0
Magri, 2016 [61] 683 49 31 3.7 Continued 25 18 - 4 - - - -
Magri, 2016 [89] 620 49 31 3.8 Not controlled 25 18 4 3 3 5 36 50
Magri, 2018 [56] 767 48 32 4.2 Continued 23 14 4 5 3 5 30 30
Masri, 2015 [90] 1005 50 36 5.5 Not controlled - 17 - 2 11 - - 126
Michaelides, 2009 [91] 81 42 30 5.3 Continued 8 6 0 6 - - 8 -
Moneghetti, 2017 [63] 131 52 37 4.7 Not controlled - - - - - - - 6
Nagata, 2003 [92] 65 50 23 6.3 Disc. (24 h) 0 0 - 0 - 0 0 0
Olivotto, 1999 [93] 126 42 29 4.7 Disc. (5H-L) 3 - 6 - - - 9 9
Peteiro, 2012 [67] 239 52 39 4.1 Continued - 2 - - 1 1 5 -
Peteiro, 2015 [94] 148 51 34 7.1 Continued 0 1 0 1 2 0 0 0
Pozios, 2018 [68] 95 49 31 3.4 Continued 0 18 0 - - - 0 0
Reant, 2015 [95] 115 52 34 1.6 Continued 0 - 1 - - - 1 -
Sadoul, 1997 [96] 161 27 35 3.7 Disc. (5H-L) 12 2 1 2 - 2 15 17
Smith, 2018 [76] 589 51 39 4.3 Continued - - - - - - - -
Sorajja, 2012 [97] 182 53 35 4.0 Continued 2 - 1 - - - 10 18
SCD: sudden cardiac death, ICD: implantable cardioverter defibrillator discharge, HFm: heart failure-related mortality, Res: resuscitation, Str: stroke,
HT: heart transplantation, CVm: cardiovascular mortality, All: all-cause mortality. Age and follow-up (F-up) are expressed in years. Other abbreviations
can be found in Table 1.
Fourteen publications identified exercise-related predictors of SCD, 13 for heart failure
death and 15 for all related mortality. VO2max (n = 7 publications), ATVO2 (n = 4), METS
(n = 6), % of age-gender predicted VO2max (n = 7), % of age-gender predicted METs (n = 1),
ABPRE (n = 7), and ventricular arrhythmias (n = 6) were significantly associated with major
outcomes as individual predictors. Individual hazard ratios extracted from each study
are presented in Table 3. Furthermore, data regarding functional capacity of groups of
patients who suffered from any of the aforementioned events and patients free of events
were extracted and meta-analyzed to elucidate differences in VO2max. Only 6 publications
had detailed information of 3684 patients concerning this parameter. Mean VO2 max was
reduced in patients who reached the combined cardiovascular death outcome compared to
those who survived (−6.20 mL·kg−1·min−1; CI 95%: −7.95, −4.46; p < 0.01; Figure 7).
Figure 7. Random-effects meta-analysis of VO2max values of patients with recorded events during follow up compared to
event-free patients. Grey squares represent mean difference between groups and its size indicates its relative weight in the
meta-analysis. Grey lines intersecting them horizontally represent 95% CI for the mean differences. The black rhombus
represents the mean difference of all studies, indicating that ‘events’ patients had lower VO2max than ‘event-free’.
J. Clin. Med. 2021, 10, 2312 15 of 24
Table 3. Univariate hazard ratio of functional assessment derived parameters for composite endpoints.
Author, Year VO2max AT VO2 METs % VO2 ABPRE Arrhythmia
Coats, 2014 [28] 0.79 (0.74–0.83) 0.71 (0.62–0.82) - - 2.15 (1.58–2.94) 1.66 (1.23–2.23)
Desai, 2014 [32] - - 0.73 (0.63–0.85) - 1.96 (0.20–3.27) 1.25 (0.51–3.10)
Feneon, 2016 [86] - - 0.99 (0.96–1.02) - - -
Finocchiaro, 2015 [37] 0.52 (0.45–0.60) - - 5.36 (1.96–14.6) † - -
Ghiselli, 2019 [39] - - 0.68 (0.53–0.87) - - -
Gimeno, 2009 [87] - - - - - 2.18 (1.07–4.45)
Magri, 2016 [55] 0.91 (0.85–0.98) 0.82 (0.72–0.94) - 0.96 (0.93–0.99) 2.33 (1.003–5.4) 3.13 (1.38–7.01)
Magri, 2016 [89] 0.80 (0.76–0.84) 0.81 (0.74–0.88) - 0.94 (0.92–0.95) 4.49 (2.91–6.93) -
Magri, 2018 [56] 0.85 (0.81–0.89) - - 0.95 (0.94–0.97) 3.50 (2.22–5.31) 3.00 (1.22–7.39)
Masri, 2015 [90] - - - 0.96 (0.93–0.98) - -
Michaelides, 2009 [91] - - - - 3.6 (0.8–15.6) -
Moneghetti, 2017 [63] 0.57 (0.42–0.76) - 0.55 (0.41–0.75) 0.59 (0.46–0.76) - -
Olivotto, 1999 [93] - - - - 4.50 (1.1–20.1) -
Peteiro, 2012 [67] - - 0.74 (0.63–0.86) - - 3.13 (1.128.71)
Sorajja, 2012 [97] 0.92 (0.89–0.96) 0.99 (0.99–0.99) 0.81 (0.71–0.93) 0.98 (0.96–0.99) - -
VO2max: peak oxygen consumption, ATVO2: oxygen consumption at the anaerobic threshold, METs: metabolic equivalents, %VO2: percentage of
age-gender predicted VO2max, ABPRE: abnormal blood pressure response to exercise. †: univariate hazard ratio for reaching composite endpoints
when %VO2 is <80%.
4. Discussion
The systematic review of the available data on cardiopulmonary functional assessment
of patients with HCM presented here highlights a need for the standardization of the
protocols and provides a comprehensive evaluation of the determinants of exercise capacity.
The dissection of 69 studies meeting selection criteria, including a large cohort of 11,672
patients, demonstrated the role of objective exercise capacity evaluation for identification of
symptomatic limitations. A mean VO2max of 23.5 (21.6, 25.3) ml·kg−1·min−1 characterizes
a disease with a reduction in exercise capacity of at least a 20% from that expected for
similar age general population [28,37].
4.1. Clinical and Prognostic Value of CPET
Despite not significant differences were seen regarding age groups, presence or ab-
sence of obstruction and the degree of hypertrophy in the achieved VO2max, this summary
variable (VO2max) demonstrated to have prognostic implications. The group of patients
with reported events had −6.20 (−9.95, −4.46) ml·kg−1·min−1 compared to the group
with no events during follow-up (43,794 patient years followed). This association has been
consistently demonstrated in several publications [28,37,55,67,89].
The results of the pooled analysis of the largest cohort of patients undergoing car-
diopulmonary functional assessment, provides relevant information of the magnitude of
different characteristics of this relatively common condition. The proportion of resting
obstruction was in the range of previous publications 31% [5,6]. This figure increased
to 49% with the inclusion of exercise induced obstruction [6]. The mean prevalence of
ABPRE was 20%, with a positive statistical association with the degree of hypertrophy
and young adult age. The proportion of ABPRE was unexpectedly significantly lower in
the obstructive vs. non-obstructive groups. The pooled analysis presented here provides
relevant information on less reported aspects such as the proportion of patients with MR at
rest (34%) which parallel to obstruction, increased with exercise to a 62%. Mean pooled
PCPW during exercise despite a significant proportion of patients with obstruction and
MR seemed to remain relatively low (11.9 ± 5.6 mmHg). The prevalence of arrhythmias
during exercise was rarely reported in the range of 2–5% for different group analysis.
Patients with chronic cardiac diseases tend to accommodate their life activities to their
physical capacity. CPET has demonstrated to be a safe and objective way to assess clinical
limitations to exercise in HCM patients [98]. The risk of developing severe arrhythmic
complications such as sustained ventricular tachycardia or fibrillation during exercise test
has been reported to be very low (0.2%) [87]. Cardiopulmonary tests, irrespective of the
protocol, seemed to be well tolerated and safe in terms of severe complications. Exercise
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test is valuable for guiding the response to medication and invasive septal reduction
therapies. Furthermore, CPET assessment and VO2max measurement are mandatory in
the evaluation of end-stage candidates for heart transplant.
ABPRE in patients between 18–40 years old and exercise NSVT have been associated
with the occurrence of sudden death during follow up of patients with HCM. The use of
ABPRE as a prognostic marker has been limited by lack of reproducibility of the variety
of exercise protocols between clinical groups [87,99]. Current sudden death prediction
scores do not include parameters of exercise performance [100]. Syncope but not dyspnea
has been shown to identify patients at risk of an arrhythmic event. The pooled analysis
presented here with up to 9145 patients from 23 publications, confirm the association
between a reduced VO2max and cardiovascular outcomes and major arrhythmic events
(Figure 7 and Table 3).
4.2. Exercise Protocols
One of the main conclusions of this systematic review is the demonstration of a wide
variety of exercise protocols. This aspect, thus, deserves a dedicated discussion. The
heterogeneity found in CPET methodologies hinders further comparisons of the results
between studies. Other authors have criticized this matter previously, highlighting that
CPET methodology is frequently selected based on convenience criteria due to the avail-
ability of specific equipment in laboratories [101]. Furthermore, previous investigations
have found differences in the VO2max achieved in treadmill and cycle-ergometer, pointing
out that a sudden intensity augment in the latter could lead to a premature ending of
the test due to peripheral fatigue [102], an avoidable matter that can also occur following
Bruce’s protocol in a treadmill [101]. At this point, ramp-like protocols with small intensity
augments repeated each few seconds emerge as a suitable and more individualized option.
These have been already used in the assessment of HCM patients with cycle-ergometers in
few studies revised here [22,23,62], and also ramp-like tests have been recently validated
in running settings [103].
Management of pharmacological therapy and previous food intake are also important
in the performance of the test due to its potential effect on its development and outcomes.
Drug management was heterogeneous, with a higher number of studies in which treatment
was not withdrawn. This decision could influence different echo-electrocardiographic
variables of the test which also have an effect on functional capacity. Moreover, meals prior
to a functional assessment should also be taken into account due to the effect of intake
on the exacerbation of symptoms of HCM symptoms [104]. LVOT increases with exercise
in postprandial conditions [105,106]. It has also been associated with alterations in the
hemodynamic response, failure to increase cardiac output, and increased pulmonary artery
pressure and pulmonary capillary pressure [107].
On the other hand, drug–food interactions may happen, as it occurs in antihyper-
tensive patients, which decrease serum zinc levels and increase glucose content [108,109].
Only 1 of the 69 studies reviewed reported withdrawal from alcohol 24 h before, while 3
indicated withdrawal from coffee but did not report on other stimulating beverages such
as tea.
4.3. Extracardiac Factors and Functional Capacity
The impact of the extracardiac factors in the functional limitation is often underesti-
mated. The average BMI of the population studied in all the publications stood at a value
considered as overweight [110]. The prevalence of diabetes was similar to that found in
general population, while that of dyslipidemia was higher [111,112]. This fact is indicative
of the need to attend the bodyweight of HCM patients and could be related to restrictions
in physical activity. Few studies include any extracardiac variables related to nutritional
status, and none of them had the word ‘nutrition’ in their full texts. Hypertension and
smoking habit were screened in 21 and 8 investigations, respectively. The first has been
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related to an increased odds ratio for reduced functional capacity, while no independent
effect was observed for smoking habit [77].
It has been shown that diabetes (OR: 2.84; 95% CI: 1.89–4.25) and the history of
hypertension (OR: 1.71; 95% CI: 1.32–2.23) have a negative effect on functional capacity,
consisting in independent predictors of a value lower than 4 METs [77], while a higher
hemoglobin content proved to be a protective factor (OR: 0.76; CI 95%: 0.65–0.68). In another
study on which patients’ VO2max was compared after stratifying by their BMI, a reduction
in VO2max was observed as BMI increased, with no differences between groups in cardiac
variables [48]. Authors suggest that the primary limitation to exercise in overweight HCM
patients may not be cardiac in origin. Olivotto and his collaborators had previously shown
that obesity is an independent risk factor associated with a phenotypic progression to severe
stages with the occurrence of adverse cardiac remodeling and in-creased left ventricular
mass [113]. Furthermore, they suggest that obesity could modulate the expression of HCM
genotype disease with severe symptoms and promote the development and progression of
symptoms of heart failure.
4.4. Exercise Prescription
Physical exercise has emerged in the last decade as a non-pharmacological, non-
surgical and safe alternative for HCM treatment, being especially effective in improving
functional capacity in patients below the threshold of 7 METs [114]. Thus, various training
protocols at intensities between 50 and 80% of heart rate reserve have suggested benefit
effect on the VO2max in individuals with HCM [115,116]. These results suggest the need
to maintain physical exercise as part of the treatment. Furthermore, a reduction in body
mass index has recently been associated with greater functional capacity [48].
Exercise prescription in patients with HCM has been derived from a wide range of
variables and different protocols. Lack of uniformity in the interpretation and adaptation
of different protocols can hamper the eligibility of the best test for an individual patient.
Lack of clarity on exercise prescription in HCM can also promote sedentarism and an
overzealous attitude amongst physicians who worry on the risk of sudden cardiac death.
4.5. Future Perspectives
Understanding of physical response to exercise in HCM and the response to therapies
has regain interest as new promising pharmacological agents have irrupted in the scene.
Mavacamten, a recently developed myosin inhibitor, has demonstrated to increase exercise
parameters and improve self-reported dyspnea class in patients with obstructive and
non-obstructive HCM [117,118].
A new paradigm shift based on recent evidence that physical training can safely
improve functional capacity in HCM patients is included in a recently published expert
consensus paper on recommendations for physical activity in Cardiomyopathies [119].
Engagement in regular physical activity improves not only quality of life in patients with
cardiomyopathies but also can prevent cardiovascular complications such as ischemic
heart disease and should be encouraged [120]. Not only functional capacity considered
as cardiovascular aerobic performance in an incremental test, but also muscular strength
might contribute to quality of life and health benefits [121]. Especially when considering
both together, concurrent aerobic and resistance training have shown beneficial effects
in cardiac patients with pathologies that share some phenotypical characteristics from
HCM [122].
Every patient with HCM requires a systematic individualised assessment. Exercise
and lifestyle advice need to be age appropriate and tailored to the patient. While prevention
of sudden cardiac death due to HCM overwhelmingly leads the initial management of
the patients, prevention of cardiovascular risk factors and loss of years of life due to
sedentarism needs to be balanced at the time of each assessment. Physiological evaluation
of patients with HCM can be complicated by the interpretation of the results on different
protocols and under different circumstances. Better understanding on the adequacy of the
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physiological testing and its limitation will empower both patients and physicians to move
from a strictly conservative approach to a more consensual and patient centred evaluation.
4.6. Limitations
There are inherent limitations of the study. Despite systematic evaluation of the
publications some of the studies reporting relevant information on functional assessment
might not be included in the analysis. Part of the cohorts might be shared in different
studies. Information from publications did not allow a dedicated analysis of subgroups
regarding gender, symptoms (presence of syncope, self-reported NYHA class), diastolic
function and heart rhythm (sinus rhythm vs. atrial fibrillation). Heterogenicity of the CPET
protocols and cohorts limit analysis and conclusions.
5. Conclusions
CPET is a valuable tool and can safely perform for assessment of physical functional
capacity in patients with HCM. VO2max is the most common performance measurement
evaluated in functional studies, showing higher values in those based on cycle-ergometer
compared to treadmill. A variety of protocols and the lack of standard protocol difficult
comparisons between studies. Subgroup analysis shows that exercise intolerance seems to
be more related to age, medication and comorbidities than HCM phenotype itself. Lower
VO2max is consistently seen in HCM patients at risk of major cardiovascular outcomes.
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